Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given average recommendation of “Moderate Buy” from analysts

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Your Free Report ) has been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $26.67.

Several analysts recently commented on the company. Piper Sandler reiterated an “overweight” rating and set a $35.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, June 5th. Truist Financial assumed coverage on Nurix Therapeutics in a report on Wednesday, July 31st. They set a “buy” rating and a $36.00 price objective for the company. Stifel Nicolaus restated a “buy” rating and set a $27.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, May 15th. Stephens initiated coverage on Nurix Therapeutics in a research report on Tuesday, May 14th. They issued an “overweight” rating and a $20.00 target price on the stock. Finally, Royal Bank of Canada boosted their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Friday, July 12th .

Check out the latest stock report on NRIX

Indoor activity

In other news, CFO Houte Hans Van sold 3,477 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $21.45, for a total transaction of $74,581.65. Following the completion of the transaction, the chief financial officer now directly owns 51,002 shares of the company’s stock, valued at approximately $1,093,992.90. The transaction was disclosed in a legal filing with the SEC, which is available on the SEC’s website. In related news, insider Christine Ring sold 1,596 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $17.01, for a total value of $27,147.96. Following the completion of the sale, the insider now owns 19,838 shares of the company’s stock, valued at approximately $337,444.38. The sale was disclosed in a legal filing with the SEC, which is available via this hyperlink. Also, CFO Houte Hans Van sold 3,477 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $21.45, for a total transaction of $74,581.65. Following the completion of the sale, the chief financial officer now directly owns 51,002 shares of the company’s stock, valued at approximately $1,093,992.90. The disclosure for this sale can be found here. Insiders have sold a total of 24,791 shares of company stock worth $506,063 over the past three months. 7.20% of shares are currently owned by corporate insiders.

Institutional investors are weighing in on Nurix Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in NRIX. Redmile Group LLC boosted its stake in Nurix Therapeutics by 37.7% in the first quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock worth $65,900,000 after purchasing an additional 1,226,497 shares during the last quarter. Affinity Asset Advisors LLC boosted its stake in Nurix Therapeutics by 176.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock worth $7,122,000 after buying an additional 440,112 shares in the last quarter. Ikarian Capital LLC acquired a new stake in Nurix Therapeutics in the 1st quarter worth $4,410,000. Candriam SCA raised its stake in Nurix Therapeutics by 30.5% in the second quarter. Candriam SCA now owns 1,164,246 shares of the company’s stock worth $24,297,000 after purchasing an additional 272,136 shares during the last quarter. Finally, Opaleye Management Inc. purchased a new stake in Nurix Therapeutics in the 1st quarter worth $3,928,000.

Nurix Therapeutics trading rose 1.5%

Shares of NRIX stock opened at $21.53 on Wednesday. Nurix Therapeutics has a 12-month low of $4.22 and a 12-month high of $24.38. The stock has a fifty day moving average price of $20.05 and a 200 day moving average price of $15.56. The firm has a market cap of $1.06 billion, a PE ratio of -7.37 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX – Get Your Free Report ) last issued its quarterly earnings data on Thursday, July 11th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.08). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The company had revenue of $12.09 million for the quarter, compared to analysts’ expectations of $19.35 million. As a group, research analysts forecast that Nurix Therapeutics will post -2.86 EPS for the current year.

Nurix Therapeutics Company Profile

(Get a free report

Nurix Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions and other diseases. The Company is developing NX-2127, an orally bioavailable Brutons tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Read more

Receive news and reviews for Nurix Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nurix Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.